| TSBP1-AS1 |
|
TSBP1 and BTNL2 antisense RNA 1
|
|
|
0.638 |
0.692 |
| MIR4435-2HG |
|
MIR4435-2 host gene
|
|
|
0.604 |
0.692 |
| CASC15 |
|
cancer susceptibility 15
|
|
|
0.603 |
0.577 |
| RTEL1-TNFRSF6B |
|
RTEL1-TNFRSF6B readthrough (NMD candidate)
|
|
|
0.682 |
0.385 |
| HLA-DRB9 |
|
major histocompatibility complex, class II, DR beta 9 (pseudogene)
|
|
|
0.682 |
0.654 |
| LINC00299 |
Q6ZSB3
|
long intergenic non-protein coding RNA 299
|
|
|
0.743 |
0.346 |
| CCNT2-AS1 |
|
CCNT2 antisense RNA 1
|
|
|
0.931 |
0.115 |
| TH2LCRR |
|
T helper type 2 locus control region associated RNA
|
|
|
0.751 |
0.385 |
| LINC01091 |
|
long intergenic non-protein coding RNA 1091
|
|
|
0.821 |
0.231 |
| SOCAR |
|
serous ovarian cancer associated RNA
|
|
|
0.821 |
0.231 |
| FLG-AS1 |
|
FLG antisense RNA 1
|
|
|
0.700 |
0.538 |
| LINC01149 |
|
long intergenic non-protein coding RNA 1149
|
|
|
0.792 |
0.346 |
| MMADHC-DT |
|
MMADHC divergent transcript
|
|
|
0.839 |
0.192 |
| HLA-DPB2 |
|
major histocompatibility complex, class II, DP beta 2 (pseudogene)
|
|
|
0.743 |
0.500 |
| HLA-DRB3 |
P79483
|
major histocompatibility complex, class II, DR beta 3
|
Immune response
|
|
0.570 |
0.885 |
| HCG17 |
|
HLA complex group 17
|
|
|
0.769 |
0.346 |
| LINC02085 |
|
long intergenic non-protein coding RNA 2085
|
|
|
0.890 |
0.115 |
| HLA-DPA3 |
|
major histocompatibility complex, class II, DP alpha 3 (pseudogene)
|
|
|
0.805 |
0.308 |
| HCG18 |
|
HLA complex group 18
|
|
|
0.722 |
0.538 |
| HAS2-AS1 |
|
HAS2 antisense RNA 1
|
|
|
0.729 |
0.269 |
| EIF2S2P3 |
|
eukaryotic translation initiation factor 2 subunit 2 beta pseudogene 3
|
|
|
1.000 |
0.077 |
| DUBR |
|
DPPA2 upstream binding RNA
|
|
|
0.861 |
0.154 |
| FAM205C |
A6NFA0
|
family with sequence similarity 205 member C
|
|
|
1.000 |
0.077 |
| MAP3K14-AS1 |
|
MAP3K14 antisense RNA 1
|
|
|
0.931 |
0.154 |
| MROH7-TTC4 |
|
MROH7-TTC4 readthrough (NMD candidate)
|
|
|
0.931 |
0.115 |